Principal Investigator: Carmine Suppa - MUSC Children's Hospital
Purpose:
There is an increasing amount of advanced therapeutic use in the treatment of pediatric IBD outside current FDA approval. This included the use of Jak inhibitors despite minimal pediatric data. What is known: jak inhibitors are efficacious in inducing and maintaining remission in adult IBD. Pediatric data remains extremely scarce. This review of the ICN network would provide the community with the largest pediatric numbers to date and ultimately, aid in insurance approvals/appeals and physician comfort with use.
Aims:
Describe jak inhibitor efficacy in the treatment of pediatric IBD. Primary outcome would be steroid free clinical remission at 1 year as defined by PUCAI, PCDAI. Secondary outcomes will include 1 year colectomy rates, clinical remission and response at 8 weeks for UC/IBDU and 12 weeks for CD. We hypothesize that remission and response rates at 1 year is going to be similar to adult literature.
Recruitment Status: This study makes use of existing data in the ICN registry. No patient recruitment at this time.
Contact: [email protected]